在阿尔茨海默氏症连续体中估计过渡概率,使用美国全国代表性的真实世界数据库
Amir Abbas Tahami Monfared1,2, Shuai Fu3, Noemi Hummel4
1Eisai Inc., 200 Metro Blvd, Nutley, NJ, 07110, USA. Amir_Tahami@eisai.com.
Neurology and therapy
|May 31, 2023
概括
阿尔茨海默氏症 (AD) 在早期阶段进展更快,从轻度认知障碍到轻度AD的过渡风险更高. 年龄较大和教育程度较低增加了阿尔茨海默症进展的风险.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 阿尔茨海默病呈现为从轻度认知障碍 (MCI) 到严重痴呆症的连续性.
- 了解疾病进展对于患者管理和研究至关重要.
研究的目的:
- 为了估计AD疾病状态之间的过渡概率.
- 为了确定影响AD进展的因素.
- 为临床试验设计和成本效益模型提供信息.
主要方法:
- 开发了一种混合效应的多态马尔科夫模型.
- 使用了健康和退休研究 (HRS) 数据库.
- 阿尔茨海默病的状态是使用修改的认知状态电话采访 (TICS-m) 定义的.
主要成果:
- 在早期的AD阶段 (MCI到轻度AD) 观察到更高的过渡概率.
- 随着时间的推移,进展风险显著增加 (估计为1年而不是10年).
- 年龄较大,教育程度较低,失业和养老院住宿与进展风险增加有关.
结论:
- 在早期的疾病阶段,阿尔茨海默病的进展风险更高,并且随着时间的推移而增加.
- 患者的人口统计和生活状况影响疾病的发展轨迹.
- 估计的概率可以指导AD管理和临床试验优化.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
相关概念视频
01:26Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226